In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Arena Pharmaceuticals, Inc.. Trade Record

NASDAQ:ARNA Arena Pharmaceuticals, Inc. stock gains 15.36% Exit Jan 11, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ARNA Dec 21, 2017, priceSeries
About Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company's proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.17
Entry Date
Dec 21, 2017
Entry Price
31.60
Sell Date
Jan 11, 2018
Sell Price
36.45
Net Gain
15.36%
Hold Time
13 Trading Days